Qilu Pharmaceutical
Biosimilar developer, China. 2 development products across 2 molecules: pegfilgrastim, ranibizumab.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Pegfilgrastim | Nylaspeg | · | under review | · | · | · | · | · | 0/7 |
| Ranibizumab | Rimmyrah QL1205 | · | Jan 2024 | MHRA | · | · | · | · | 2/7 |
Month shown is the first approval or registration of that product in that market.
In development
ClinicalTrials.gov lists three comparative trials sponsored by Qilu Pharmaceutical for three molecules: aflibercept, follitropin alfa, pegfilgrastim. Candidates without an approval yet in the seven markets: QL1012, QL1207.
| Molecule | Candidate | Developer or sponsor | Reference product | Phase | Design | Registry status | Started | Primary completion | In the Atlas | Registry record |
|---|---|---|---|---|---|---|---|---|---|---|
| Aflibercept | QL1207 | Qilu Pharmaceutical | Eylea | Phase 3 | Comparative efficacy | Completed | Aug 2019 | Jan 2022 | no approval in the seven markets | NCT05345236 |
| Follitropin alfa | QL1012 | Qilu Pharmaceutical | Gonal-f | Phase 3 | Comparative efficacy | Completed | Oct 2018 | Oct 2019 | no approval in the seven markets | NCT05149924 |
| Pegfilgrastim | QL0605 | Qilu Pharmaceutical | Neulasta | Phase 1 | Comparative PK | Unknown, last recruiting | Nov 2020 | Nov 2021 | Nylaspeg | NCT04651036 |
Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.
Companies on the same molecules
Developers whose portfolios overlap most with Qilu Pharmaceutical, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- EMAJan 2024Rimmyrah, ranibizumab
Compare Qilu Pharmaceutical with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant